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Background
Successful vaccines (e.g. tetanus) can induce long-lived
antibody levels that are maintained by long-lived plasma
cells and do not correlate with numbers of blood memory
B-cells. Early events during HIV-1 acute infection may
impair the timely onset of neutralizing antibody
responses. Thus, an effective HIV-1 vaccine should elicit
high levels of durable antibodies by long-lived plasma
cells. We asked if HIV-1 envelope-specific memory
responses are sustained by memory B-cells in the settings
of HIV-1 gp120 envelope vaccination and chronic HIV-1
infection (CHI).
Methods
Total, gp140 envelope and V3-specific IgG memory B-cells
from PBMCs of 26 CHI patients and 25 vaccinated volun-
teers from the VaxGen clinical trial VAX004 were enumer-
ated with ELISpot assays after in vitro stimulation.
Respective plasma antibody levels were tested with ELISA.
An additional 8 CHI subjects, treated with ART for
between 125 and 387 weeks and with viremia suppres-
sion, were studied for levels of anti-gp120, -gp41, -p55, -
tetanus toxoid and -influenza IgG plasma antibodies
(Luminex assay and ELISA) over time of ART to determine
the relative antibody level half-lives.
Results
Levels of anti-HIV-1 envelope plasma antibodies and
memory B-cells correlated both in CHI and vaccinated
individuals. Moreover, whereas the reported expected
half-life of plasma antibody levels to protein vaccines is
>10 years when maintained by long-lived plasma cells
(we observed ~11 years for tetanus), plasma anti-envelope
antibody level half-lives were ~33–81 weeks in ART-
induced aviremic CHI subjects. In contrast, anti-p55 Gag
antibody level half-life was 648 weeks and antibody titers
against influenza did not decay in-between yearly or bien-
nial influenza vaccine boosts.
Conclusion
These data demonstrated that HIV-1 envelope induces
predominantly short-lived memory B-cell-dependent
plasma antibodies in the settings of envelope vaccination
and chronic HIV-1 infection. The inability to generate
high titers of long-lived anti-envelope antibodies is a
major hurdle to overcome for the development of a suc-
cessful HIV-1 vaccine.
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